Probiotin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Probiotin

Property Description
Active ingredient Clindamycin Phosphate (Prodrug)
Form Topical Solution, Gel, or Lotion
Pharmacological class Lincosamide antibiotic
Common use Antimicrobial and anti-inflammatory support
Origin Semi-synthetic

What is Probiotin and What Type of Medicine is It?

Probiotin is a prescription medication containing the active compound Clindamycin Phosphate, which is classified pharmacologically as a Lincosamide antibiotic. This substance is a semi-synthetic derivative of the naturally occurring antibiotic Lincomycin. The Clindamycin Phosphate in the preparation functions as a prodrug, meaning it is chemically inactive until it is converted into the therapeutically active component, Clindamycin, upon contact with the skin. This classification establishes the drug's primary function as an antimicrobial agent that targets susceptible bacterial growth and is used to suppress certain bacterial populations. Probiotin is a brand name and is differentiated by offering the Clindamycin Phosphate in a variety of topical dosage forms, including solutions and gels, making it versatile for localized surface application.


Composition, Form, and Application Type

The formulation of Probiotin is specifically engineered for topical application and is typically available as a topical solution, topical gel, or a lotion. These dosage forms utilize an aqueous or hydrophilic vehicle to deliver the active ingredient directly to the skin surface. The purpose of the topical route is to concentrate the medication's effect locally, minimizing the amount of the antibiotic that enters the body's general circulation. This approach prioritizes activity at the site of concern with limited systemic exposure.


What is the General Purpose of Probiotin’s Action?

The general purpose of Probiotin is rooted in its ability to suppress the proliferation of certain bacteria while simultaneously mitigating inflammation. The core action of the Clindamycin component is bacteriostatic, inhibiting the production of essential proteins necessary for the survival and multiplication of susceptible organisms. Furthermore, the compound exhibits an intrinsic, independent anti-inflammatory effect that aids in reducing associated skin redness and swelling. This combination defines its general utility as an agent for dual antimicrobial and anti-inflammatory support in dermatological contexts.

Regulatory References

  1. Clindamycin Drug Record

What side effects are possible with Probiotin?

Possible Side Effects and Safety Information

Official safety information concerning products containing live microorganisms (commonly called probiotics), such as Probiotin, addresses both generally reported reactions and serious risks in vulnerable populations.

Commonly Reported Adverse Reactions

Adverse events reported most frequently are generally temporary and related to the gastrointestinal system, including an increase in gas, bloating, and mild digestive discomfort. These effects often subside with continued use as the body adjusts to the microbial change. Allergic reactions to ingredients or contaminants in the product formulation are also possible, although rare.

Serious Safety Considerations

  • Invasive Disease/Infection: The most critical safety concern is the risk of invasive, potentially fatal disease (e.g., sepsis or fungemia) caused by the live bacteria or yeast in the product. These risks are significantly higher in highly vulnerable individuals.
  • Vulnerable Populations: The U.S. Food and Drug Administration (FDA) has issued warnings against using probiotic products to treat or prevent disease in preterm infants in hospital settings. Cases of severe or fatal infections have been reported in this population, and the products are considered unapproved drugs for this use.
  • Immunocompromised Patients: Individuals who are critically ill, severely debilitated, or have compromised immune systems are at an increased risk of harmful effects, including systemic infection, from probiotic organisms entering the bloodstream.

Regulatory and Use Limitations

The FDA has not approved any probiotic product for use as a drug or biological product in infants to treat or prevent disease. The use of an unapproved product for therapeutic purposes may require an Investigational New Drug (IND) application to the agency. Other theoretical but documented risks include the production of harmful substances by the microorganisms and the transfer of antibiotic resistance genes.

Safety is best established in healthy individuals; risks must be carefully weighed against potential benefits for high-risk patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that Probiotin, which contains Clindamycin Phosphate, can be absorbed through the skin in amounts sufficient to produce systemic effects known to be associated with the lincosamide antibiotic class.

Documented Overdose Manifestations

System Affected Official Manifestations (Systemic Risk)
Gastrointestinal Diarrhea (severe, persistent, or bloody), severe abdominal cramps, and the passage of blood and mucus.

Severe Outcomes and Emergency Action

The most serious potential outcome documented is pseudomembranous colitis, which is noted in regulatory warnings as a condition that may result in patient death due to the systemic effects of the absorbed antibiotic.

Regulator-Mandated Actions:

  • Drug Discontinuation: The medication must be discontinued immediately if significant diarrhea develops.
  • Urgent Medical Help: Urgent medical attention is required for accidental ingestion or if acute, severe symptoms such as collapse, difficulty breathing, or inability to be awakened occur. The poison control helpline should be contacted in cases of suspected overdose.

Management Notes:

The official labeling confirms that no specific antidote is known for clindamycin overdose. Management focuses on providing symptomatic and supportive treatment. Specific procedural notes advise against the use of antiperistaltic agents, as they may prolong or worsen the underlying condition.

Therapeutic Uses of Probiotin

What Probiotin Treats: Main Uses and Benefits

Probiotin (Topical Clindamycin Phosphate) is commonly used across conditions presenting with acne vulgaris, helping to manage the symptomatic discomfort associated with the condition and its manifestations. The application is within domains where additional symptomatic support is generally needed.

Targeting Inflammatory Pimples and Associated Discomfort

This topical medication is generally applied in addressing the mild to moderate forms of acne that feature clusters of symptoms that may become intense or disruptive, such as red papules and pus-filled pustules. It is commonly used to help with the visible manifestations that create noticeable physiological strain. The therapeutic intent is generally to address the bacterial component that contributes to the formation of these distressing manifestations. This generally provides support that helps ease the overall symptom load during periods of heightened symptoms.

Soothing Redness and Supporting Stability

Probiotin is also relevant in contexts marked by increased discomfort due to acne, as it supports the management of pronounced inflammatory symptoms like redness and swelling. This is helpful in situations where multiple symptoms occur together and interfere with daily comfort. By assisting with maintaining stability and providing supportive relief, the medication helps improve day-to-day comfort during symptomatic periods, and may assist with coping more steadily with symptom fluctuations.


Quick Fact: Relief for Inflammatory Acne Probiotin is commonly used across conditions characterized by periods of heightened symptoms related to inflammatory acne lesions in adolescents and adults. Its application is relevant within therapeutic areas involving heightened responses like papules, pustules, redness, and swelling.

Regulatory References

  1. DailyMed drug labeling

Eligibility and Restrictions for Use

Eligibility for Probiotin (Topical Clindamycin Phosphate)

Official regulatory guidelines strictly define the populations permitted and prohibited from using Probiotin, which contains the Lincosamide antibiotic, Clindamycin Phosphate.

Absolute Contraindications

Probiotin must not be used by individuals with a history of:

  • Hypersensitivity (allergy) to Clindamycin, Lincomycin, or any component of the topical formulation.
  • Gastrointestinal Disorders, including a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (such as pseudomembranous colitis).

Age-Related Eligibility and Restrictions

Population Group Eligibility Status
Adults and Adolescents Allowed (Established for ages 12 and older).
Children under 12 Use Not Established (Safety and effectiveness have not been proven).

Conditional Use (Caution Required)

Use is conditional during pregnancy and lactation. The official regulatory stance advises that the medication should be used only if clearly needed, and caution must be exercised in nursing women, as Clindamycin is known to be excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Probiotin (Topical Clindamycin Phosphate) possesses an official interaction profile focused on pharmacodynamic effects and local administration constraints, reflecting the medicine's low systemic absorption. Regulatory documents establish two primary categories of drug-drug interaction patterns.

The first documented pattern involves pharmacodynamic reinforcement. Clindamycin exhibits intrinsic neuromuscular blocking properties that may enhance the action of other medicinal products in the neuromuscular blocking agent class. A second documented pattern involves pharmacodynamic antagonism. Regulatory labeling advises against the co-administration of Probiotin with any product containing Erythromycin, as antagonism has been demonstrated between clindamycin and erythromycin.

Interaction-Related Restrictions

Official labeling also defines constraints related to co-administered topical agents and systemic management:

  • Local Additive Effect: The use of Probiotin concurrently with other peeling, desquamating, or abrasive topical acne therapies may result in a cumulative irritancy effect on the skin.
  • Systemic Management Constraint: The use of antiperistaltic agents (such as opiates or diphenoxylate with atropine) may prolong and/or worsen severe colitis, which is a potential adverse reaction associated with clindamycin absorption.

No formal interactions with food, alcohol, or herbal products are documented in the official regulatory prescribing information for this topical formulation, nor are any interactions involving cytochrome P450 enzymes.

Mechanism of Action

The physiological effect of Clindamycin is achieved through two distinct and complementary mechanisms that together result in a change in local biological conditions.

Molecular Targeting of Bacterial Protein Synthesis

This mechanism involves the drug's precise binding to the 23S Ribosomal RNA within the 50S ribosomal subunit of susceptible bacteria. This molecular inhibition blocks the required protein synthesis pathway, leading to the cessation of bacterial replication and a consequential decrease in the density of the microbial population.

Modulation of Local Immune Signaling

Independent of its antibacterial action, Clindamycin acts as a modulator of local immune signaling. The compound achieves this by reducing the production of chemotactic factors and other inflammatory mediators, thereby limiting the migration of immune cells and attenuating the local physiological inflammatory reaction.

Constraints on Mechanistic Efficacy

The drug's primary action is prevented when target bacteria develop structural changes, such as methylation of the 23S rRNA (MLSb resistance). This modification blocks Clindamycin from achieving the necessary binding to the 50S subunit, which results in the inability to inhibit protein synthesis.

Dosage and Administration Information

How Probiotin is Used: Administration Principles

Probiotin, which contains the active ingredient Clindamycin Phosphate, is administered via the topical route directly onto the skin. This route ensures concentrated local delivery and is consistent across the available dosage forms, which include solution, gel, and lotion formulations.


Administration Scope

Feature Guideline
Route of administration Topical (Application to the skin surface only).
Dosing schedule Apply a thin film of the 1% medication to the entire affected area where lesions appear.
Frequency pattern Twice daily is the standard for most solutions and lotions, though some specific gel or foam formulations are labeled for once-daily use.
Age-group rules Indicated for patients 12 years of age and older.

Resulting Procedural Structure

The use protocol involves the area to be treated being gently washed, rinsed, and patted dry before application. When using the lotion or suspension forms, the product is to be shaken well immediately prior to use. Application is intended to avoid contact with the eyes, mouth, lips, or other mucous membranes. The instructions indicate that the patient's response is generally assessed after approximately 8 to 12 weeks of continuous use, which defines the typical initial course of treatment. If a scheduled application is missed, it is typically applied as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed application is skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Probiotin


Evidence for Use in Mild to Moderate Acne Vulgaris

The body of research for Probiotin (Topical Clindamycin Phosphate) includes Randomized Controlled Trials (RCTs). These are studies where participants are randomly assigned to receive either the medicine or a non-active formulation, known as a vehicle or placebo. This design is relevant in trials that assess short-term or episodic symptom patterns. These studies focused on individuals diagnosed with mild to moderate acne vulgaris and monitored outcomes linked to inflammatory or irritative states.

The research examined changes over defined time intervals, with follow-up durations typically assessed at 12 weeks in pivotal trials. The primary measurements used in these trials included objective measures of change from baseline for lesion counts, specifically focusing on inflammatory lesions such as papules and pustules. Researchers also utilized the Investigator's Global Assessment (IGA), a categorical score, to monitor overall status. Findings describe patterns observed in the studies related to changes in symptoms that were measured in the observed populations during the trial period.


The Role of Vehicle-Controlled Trials in Evaluation

Key clinical evaluations were structured as comparative studies, assessing the measurements related to the medicine against the vehicle-only control group. These studies monitored outcomes related to physical discomfort and episodic changes in acne symptoms. For instance, studies monitored metrics such as the percent change from baseline for the number of inflammatory lesions observed over the study period.

Research includes the assessment of a defined success rate in trials, which involves measuring the proportion of participants who achieved specific IGA scores. These findings help contextualize the measured outcomes reported under the specific conditions of the clinical trials.


Long-Term Research and Follow-up Duration

The research used for assessment tends to focus on short-term outcomes. The follow-up durations were typically assessed at 12 weeks in the pivotal efficacy trials that examined the medicine.

The research exploring short-term symptom changes primarily focuses on the initial treatment phase. Therefore, there is limited information for long-term outcomes. Data for sustained or long-term effects beyond the 12-week trial period are not fully established in the core regulatory evidence. Research examining temporary physiological imbalance and sustained stability is an area where data are still emerging.


Evidence in Specific Patient Populations

The primary research for Probiotin was observed in populations defined as adolescents and adults aged 12 years and older. These are the groups presenting with conditions involving periods of heightened symptoms (mild to moderate acne) where the research examined short-term symptom changes.

Data for certain groups remain insufficient. For instance, there is limited information available from dedicated trials focusing on older adults, pregnant individuals, or those with various concurrent medical conditions, as these groups were often excluded from the main clinical trials. Consequently, results apply only to the populations studied.


Key Limitations and Areas of Research Uncertainty

The research on Probiotin, while generally supported by high-quality RCTs, still presents certain limitations that shape clinical discussions. The research record includes documentation regarding the potential for the development of antibiotic resistance in the bacteria associated with acne (Cutibacterium acnes). This research finding was associated with patterns examined in studies comparing monotherapy versus combination therapy.

Furthermore, studies suggest that the core research focused primarily on inflammatory symptoms. Comparative evidence is lacking regarding the measurements of change for non-inflammatory lesions (comedones) when compared directly to other topical agents specifically designed to address those manifestations. This evidence highlights what is known—and what is still uncertain—about the medicine’s broad activity in conditions where symptoms may vary in intensity.

Key Studies & References

  1. Clindamycin phosphate topical solution, gel, and lotion official label (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Probiotin (FAQ)


Q: How quickly do people typically start to notice any effects from Probiotin?

A: Official instructions establish that the patient’s response to treatment is generally assessed after approximately 8 to 12 weeks of continuous use. This timeframe indicates the period used for clinical monitoring of initial treatment response.


Q: Are there any common foods or drinks that should be avoided when taking Probiotin?

A: Probiotin is a topical medication applied directly to the skin. According to the official regulatory prescribing information for this topical formulation, no formal interactions with food or alcohol are documented.


Q: Does Probiotin affect the ability to drive or operate machinery?

A: Official drug documentation notes that no effects on the ability to drive or use machinery have been reported with the topical product.


Q: Are there different versions or strengths of Probiotin available?

A: Probiotin contains the active ingredient Clindamycin Phosphate, typically at a 1% concentration. It is available in different topical dosage forms, including solutions, gels, and lotions.


Q: Can Probiotin be taken long-term for several months?

A: The pivotal efficacy trials that examined this medicine primarily focused on outcomes assessed up to 12 weeks. Because of this, data for sustained or long-term effects beyond the initial trial period are not fully established in the core regulatory evidence.


Q: What should a person do if they experience mild stomach discomfort after starting Probiotin?

A: Adverse events related to the digestive system, such as mild discomfort or bloating, are generally temporary and have been commonly reported. Official information describes that these temporary effects often subside with continued use.


Q: Does Probiotin interact with common dietary supplements like vitamins or herbal remedies?

A: The official regulatory prescribing information for this topical formulation documents no formal interactions with herbal products. As with all medications, any concurrent use with supplements involves careful consideration.


Q: What is the risk of developing a serious allergy to Probiotin?

A: A history of hypersensitivity, or allergy, to clindamycin or lincomycin is considered an absolute contraindication for use. Hypersensitivity reactions are listed as possible adverse events.


Q: Does Probiotin contain any common allergens like gluten or lactose?

A: The official documentation lists the active ingredient, Clindamycin Phosphate, but the complete list of inactive ingredients, or excipients, is not universally published. This limits the ability to confirm the presence or absence of all common allergens like gluten or lactose.


Q: If someone is taking multiple medications, how should they check for interactions with Probiotin?

A: Official labeling defines that drug interactions are possible, such as antagonism with the antibiotic Erythromycin or reinforcement of neuromuscular blocking agents. Concurrent use with any other medications involves considering known interactions.


Q: How do researchers measure the effects of Probiotin in clinical trials?

A: In clinical trials, researchers typically measure the drug's effects using objective tools. These include counting the number of inflammatory lesions (papules and pustules) and using a categorical score called the Investigator's Global Assessment (IGA) to monitor overall skin status.


Q: If a person feels better, can they stop taking Probiotin immediately?

A: The official instructions establish that the typical initial course of treatment is assessed after approximately 8 to 12 weeks of continuous use. Decisions regarding the duration or cessation of use are often made in relation to this assessment period.


Q: Does Probiotin require a prescription from a doctor?

A: According to regulatory classification, Probiotin is consistently defined as a prescription medication.


Q: What happens if a person forgets to take Probiotin for one day?

A: The official guidance for a missed application is to apply the missed dose as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed application should be skipped.


Q: Do older adults (seniors) need to use a different amount of Probiotin?

A: The primary research establishing safety and effectiveness was observed in adolescents and adults aged 12 years and older. Dedicated trials focusing on older adults have provided limited information regarding specific usage.


Q: Are there any common skin reactions or rashes associated with Probiotin?

A: Yes, regulatory documents list common local skin reactions associated with the topical product. These often include dryness, peeling, itching, burning, and redness of the treated area.


Q: Are there any specific lifestyle changes that are often suggested while using Probiotin?

A: The official use protocol includes specific preparation steps. It requires that the area to be treated be gently washed, rinsed, and patted dry before the application of the medication.


Q: Can Probiotin be split or crushed to make it easier to swallow?

A: Probiotin is a topical medication, typically available as a solution, gel, or lotion. It is not formulated as an oral medication; the approved route is topical application to the skin.


Q: Can Probiotin be taken on an empty stomach?

A: Since Probiotin is administered via the topical route (applied to the skin), its use is not dependent on stomach contents or the timing of meals.


Q: Is Probiotin available to buy over-the-counter in some countries?

A: In the countries with documented regulatory classifications, Probiotin is consistently defined as a prescription medication.


Q: What is the typical difference between Probiotin tablets and capsules?

A: Probiotin is available only in topical dosage forms, such as solution, gel, and lotion, for application to the skin. It is not supplied as oral tablets or capsules.


Q: Is there a specific regulatory classification for Probiotin (e.g., Schedule I, II, etc.)?

A: Probiotin is classified as a Lincosamide antibiotic and a prescription medication. Regulatory documents do not list the topical formulation in the Controlled Substance schedules (Schedule I-V).


Q: Can Probiotin be taken during religious fasting periods?

A: The drug is strictly administered via the topical route, meaning it is applied directly to the skin surface. Its use is generally not restricted by periods of fasting.


Q: Can Probiotin be taken with milk or other dairy products?

A: Probiotin is a topical formulation. The official regulatory prescribing information for this topical product documents no formal interactions with food, including milk or dairy products.


Q: Does Probiotin need to be stored in the refrigerator?

A: The official regulatory requirement is to store the product at Controlled Room Temperature, typically 20 C to 25 C. The product must be protected from freezing.


Q: Are the side effects of Probiotin generally mild or severe?

A: The commonly reported adverse reactions are often mild and transient in nature, related to minor discomfort. However, the official safety information also addresses serious risks, which are significantly higher in highly vulnerable individuals.


Q: Does Probiotin change the results of routine blood tests?

A: The product is specifically engineered for topical application to concentrate the medication's effect locally. This approach is designed to minimize the amount of the antibiotic that enters the body's general circulation.


Q: Is Probiotin associated with any long-term health risks?

A: Research used for regulatory assessment primarily focuses on short-term outcomes (up to 12 weeks). Documentation exists regarding the potential for the development of antibiotic resistance in acne-associated bacteria.


Q: Can Probiotin cause mood changes or anxiety?

A: Regulatory documents list anxiety as an adverse event that has been reported, though it is considered rare based on available clinical trial data.

How should Probiotin be stored and disposed of?

How to Store and Dispose of Probiotin?

Probiotin (Clindamycin Phosphate topical products) must be stored and handled according to the official requirements detailed in regulatory labeling.

Storage & Disposal Scope Official Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature, 20 C to 25 C.
Prohibited Environments Protect from freezing. Do not store the product in direct sunlight or above mathbf120 F (mathbf49 C) for foam formulations.
Flammability/Handling Avoid fire, flame, and smoking near alcohol-based solutions or foams. Pressurized foam containers must not be punctured or incinerated.
Container Rules Keep the container tightly closed and do not use single-use applicators if the seal is broken.
Child Safety The medication must be kept out of the reach of children.
Disposal Instructions Discard single-use applicators after use. Any unused medicine dispensed from a foam can should be thrown away immediately.

Regulatory labeling establishes these mandatory conditions, which define the environment, temperature constraints, fire and heat avoidance for pressurized forms, and child protection rules for the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Probiotin found in:

A-Z Index: